EUVIMEDEUVIMED entdecken
Crossref

Withaferin-A alleviates acute graft versus host disease without compromising graft versus leukemia effect

Saurabh Kumar Gupta, Dievya Gohil, Deepshikha Dutta, Girish Ch Panigrahi, Puja Gupta, Kajal Dalvi, Twinkle Khanka, Subhash Yadav, Rajiv Kumar Kaushal, Akanksha Chichra, Sachin Punatar, Anant Gokarn und 9 weitere

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Saurabh Kumar Gupta und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India; Homi Bhabha National Institute, …. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute graft versus host disease (aGvHD) contributes to a significant proportion of non-relapse mortality and morbidity in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). Withaferin-A (WA), a phytomolecule obtained from Withania somnifera (Ashwagandha), is known to have anti-inflammatory, anti-proliferative and immunomodulatory properties. The efficacy of WA for the prevention and treatment of aGvHD was evaluated using a murine model of alloHSCT. Prophylactic administration of WA to mice mitigated the clinical symptoms of aGvHD and improved survival significantly compared to the GvHD control [HR = 0.07 (0.01-0.35); P < 0.001]. Furthermore, WA group had better overall survival compared to standard prophylactic regimen of CSA + MTX [HR = 0.19 (0.03-1.1), P < 0.05]. At the same time, WA did not compromise the beneficial GvL effect. In addition, WA administered to animals after the onset of aGvHD could reverse the clinical severity and improved survival, thus establishing its therapeutic potential. Our findings suggest that WA reduced the systemic levels of Th1, Th2 and Th17 inflammatory cytokine and increased the anti-inflammatory cytokine IL-10 levels significantly (P < 0.05). WA also inhibited lymphocytes migration to gut, liver, skin and lung and protected these organs from damage. Ex-vivo, WA inhibited proliferation of human peripheral blood mononuclear cells (hPBMCs), modulated immune cell phenotype and decreased cytokine release. In addition, WA inhibited pJAK2 and pSTAT3 protein levels in mouse splenocytes and hPBMCs. In conclusion, our study demonstrates the utility of WA for the prevention and treatment of aGvHD, which should be further evaluated in a clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemiaHumansAnimalsMiceGraft vs Leukemia EffectLeukocytes, MononuclearCytokinesAnti-Inflammatory AgentsAcute Disease

Stichwörter der Autor:innen

Acute graft versus host disease (aGvHD)Allogeneic hematopoietic stem cell transplantation (alloHSCT)Graft versus Leukemia (GvL)JAK2-STAT3 signalingProphylaxisTreatmentWithaferin-A (WA)

Substanzen

CytokinesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India; Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai 400094, Maharash…
  • Cell and Tumor Biology Group, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India; Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai 400094, Maharashtra, In…
  • Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India.
  • Hematopathology Laboratory, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India.
  • Department of Pathology, Tata Memorial Hospital, Parel, Mumbai 400012, Maharashtra, India; Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai 400094, Maharashtra, India.
  • Department of Medical Oncology, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India; Homi Bhabha National Institute, BARC Training School Complex, Anushakti Nagar, Mumbai 400094, Maharashtra,…

Förderung

  • Tata Memorial Centre
  • Advanced Centre for Treatment, Research and Education in Cancer

Zitieren

APA

Kumar Gupta, S., Gohil, D., Dutta, D., Panigrahi, G. C., Gupta, P., Dalvi, K., Khanka, T., Yadav, S., Kumar Kaushal, R., Chichra, A., Punatar, S., Gokarn, A., Mirgh, S., Jindal, N., Nayak, L., Tembhare, P. R., Khizer Hasan, S., Kumar Sandur, S., Hingorani, L., …, & Gota, V. (2023). Withaferin-A alleviates acute graft versus host disease without compromising graft versus leukemia effect. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110437

Vancouver

Kumar Gupta S, Gohil D, Dutta D, Panigrahi GC, Gupta P, Dalvi K, et al. Withaferin-A alleviates acute graft versus host disease without compromising graft versus leukemia effect. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110437

BibTeX
@article{KumarGupta2023,
  author = {Kumar Gupta, Saurabh and Gohil, Dievya and Dutta, Deepshikha and Panigrahi, Girish Ch and Gupta, Puja and Dalvi, Kajal and Khanka, Twinkle and Yadav, Subhash and Kumar Kaushal, Rajiv and Chichra, Akanksha and Punatar, Sachin and Gokarn, Anant and Mirgh, Sumeet and Jindal, Nishant and Nayak, Lingaraj and Tembhare, Prashant R and Khizer Hasan, Syed and Kumar Sandur, Santosh and Hingorani, Lal and Khattry, Navin and Gota, Vikram},
  title = {Withaferin-A alleviates acute graft versus host disease without compromising graft versus leukemia effect},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110437}
}
Kostenlos starten →